Genomma Lab Internacional S.A.B. de C.V.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Genomma Lab Internacional S.A.B. de C.V. - overview
Established
1996
Location
Mexico City, Ciudad de Mexico, Mexico
Primary Industry
Pharmaceuticals
About
Genomma Lab Internacional is a Mexican company focused on developing and marketing health and personal care products, including over-the-counter medications and personal care items tailored to various consumer needs. Founded in 1996, Genomma Lab Internacional is headquartered in Mexico City, Mexico. The company is known for its focus on health and personal care products and has undergone no significant pivots or changes in its business operations since inception. Rodrigo Aspra is the founder of the company, and Jorge Brake serves as the CEO.
The company has successfully raised a total of USD 233. 60 mn through multiple funding rounds, with the latest being an IPO completed in December 2009, which raised USD 233. 60 mn from the sale of 130. 9 million shares at USD 1.
54 per share. Genomma Lab Internacional specializes in a diverse array of health and personal care products designed to address various consumer needs. Their core offerings include over-the-counter medications and personal care items aimed at treating conditions such as skin ailments, hair loss, intimate health issues, and respiratory problems. Notable brands within their portfolio consist of Tío Nacho for hair care, Cicatricure for skin treatments, and several products aimed at pain relief, hydration, and digestive health.
These products are formulated to be safe, effective, and innovative, targeting a broad clientele that ranges from individual consumers to healthcare professionals. Genomma Lab's products are distributed widely across Latin America, including significant markets in Mexico, Argentina, Brazil, and Colombia, ensuring accessibility for diverse populations seeking to improve their health and well-being. In 2023, Genomma Lab Internacional generated revenue of USD 929. 98 mn with an EBITDA of USD 197.
80 mn. The company's revenue is facilitated through a multi-faceted distribution model that includes direct sales, partnerships with retailers and wholesalers, and collaborations with pharmacies, ensuring a steady flow of products to end users. Flagship products like Tío Nacho and Cicatricure significantly contribute to the company's revenue, appealing to a wide range of consumers seeking effective health solutions. Genomma Lab Internacional is strategizing for future growth through the development of new products aimed at enhancing its market presence.
The company is targeting expansion into additional markets, specifically focusing on broader reach within Latin American countries by 2025. The funding from the IPO will be utilized to support these initiatives, aiming to enhance product innovation and strengthen distribution channels. As of December 2009, the company's funding strategy included a secondary offering to realize stakeholder value.
Primary Industry
Pharmaceuticals
Sub Industries
Beauty & Hygiene, Pharmaceuticals
Website
www.genommalab.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Genomma Lab Internacional S.A.B. de C.V. - timeline of key events
Genomma Lab Internacional S.A.B. de C.V. - financials
| Fiscal Year Ended | Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 6,263,621,000 | 8,074,787,000 | 9,799,690,000 | 11,360,689,000 | 11,540,998,000 | 11,042,452,000 | 11,316,310,000 | 12,078,443,000 | 11,794,419,000 | 12,712,890,000 | 13,870,148,000 | 15,487,059,000 | - | - | - |
| % Revenue Growth (YoY) | - | 28.9% | 21.4% | 15.9% | 1.6% | (4.3%) | 2.5% | 6.7% | (2.4%) | 7.8% | 9.1% | 11.7% | - | - | - |
| EBITDA (USD) | 1,693,541,000 | 2,139,158,000 | 2,558,468,000 | 3,001,135,000 | 2,543,117,000 | (856,989,000) | (1,583,158,000) | 2,601,178,000 | 2,382,260,000 | 2,473,020,000 | 2,943,355,000 | 3,228,933,000 | - | - | - |
| Operating Income (USD) | 1,614,791,000 | 2,057,214,000 | 2,492,121,000 | 2,936,892,000 | 2,445,096,000 | (975,222,000) | (1,666,964,000) | 2,531,373,000 | 2,301,096,000 | 2,330,822,000 | 2,768,002,000 | 3,046,551,000 | - | - | - |
| Operating Margin | 25.8% | 25.5% | 25.4% | 25.9% | 21.2% | (8.8%) | (14.7%) | 21.0% | 19.5% | 18.3% | 20.0% | 19.7% | - | - | - |
| % EBITDA Margin | 27.0% | 26.5% | 26.1% | 26.4% | 22.0% | (7.8%) | (14.0%) | 21.5% | 20.2% | 19.5% | 21.2% | 20.8% | - | - | - |
| NET Income (USD) | 1,092,958,000 | 1,415,954,000 | 1,605,968,000 | 1,810,610,000 | 1,507,106,000 | (1,012,637,000) | (1,642,791,000) | 1,406,488,000 | 1,109,465,000 | 764,463,000 | 1,470,378,000 | 1,307,867,000 | - | - | - |
| % Net Margin | 17.4% | 17.5% | 16.4% | 15.9% | 13.1% | (9.2%) | (14.5%) | 11.6% | 9.4% | 6.0% | 10.6% | 8.4% | - | - | - |
Genomma Lab Internacional S.A.B. de C.V. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Private Placement/Follow on | Completed | Genomma Lab Internacional S.A.B. de C.V. | - | ||||||||
| IPO | Completed | Genomma Lab Internacional S.A.B. de C.V. | - | ||||||||
| Trade Sale | Completed | Grupo Comercial e Industrial Marzam S.A. de C.V | - | ||||||||
| Growth | Completed | Genomma Lab Internacional S.A.B. de C.V. | - |
Displaying 1 - 4 of 4
Genomma Lab Internacional S.A.B. de C.V. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.